Tender Offer | ₹750.00 Crores | Listed at BSE, NSE | Thu, Jun 23, 2022 - Wed, Jul 6, 2022
Zydus Lifesciences Ltd. Buyback is a tender offer for the repurchase of up to 1.15 crore equity shares at a buyback price of ₹650 per share with a face value of ₹1 per share, aggregating to ₹750.00 crores.
The record date for determining eligible shareholders is Jun 2, 2022. Shareholders holding equity shares as on the record date are eligible to participate in the buyback.
The buyback opens on Jun 23, 2022 and closes on Jul 6, 2022, with the last date for receipt of tender forms being Jul 6, 2022.
The finalisation of buyback acceptance is expected on Jul 14, 2022, followed by settlement of bids on Jul 15, 2022.
ICICI Securities Ltd. is the Manager to the Buyback and MUFG Intime India Pvt.Ltd. is the Registrar and ICICI Securities Limited is the Registered Broker to the Buyback.
Investors are advised to refer to the Zydus Lifesciences Ltd. Letter of Offer for detailed information, including eligibility criteria, entitlement ratio, acceptance methodology, and tax implications.
Offer Opening Date
Thu, Jun 23, 2022
Offer Closing Date
Wed, Jul 6, 2022
Buyback Price
₹650 per share
Record Date
June 2, 2022
| Category | Entitlement Ratio of Buyback |
|---|---|
| Reserved Category for Small Shareholders | 26 Equity Share out of every 503 Fully paid-up Equity Shares held on the Record Date. |
| General Category for all other Eligible Shareholders | 1 Equity Shares out of every 101 Fully paid-up Equity Shares held on the Record Date. |
| Particulars | For the year/period ended (Rs. in Million) | ||
|---|---|---|---|
| 31-Mar-22 | 31-Mar-21 | 31-Mar-20 | |
| Total Income | 1,54,899 | 1,51,394 | 1,43,670 |
| Profit After Tax | 23,726 | 21,850 | 12,044 |
| Net Worth | 1,69,996 | 1,29,923 | 1,03,757 |
Zydus Lifesciences Limited is a leading Indian Pharmaceutical company that offers healthcare services globally. The company manufactures formulations, APIs, vaccines, biosimilars, complex products (transdermals, topical etc.), animal health products as well as wellness products.
Zydus Lifesciences Limited has more than 30 manufacturing plants worldwide including India, Germany, Brazil & USA. Zydus Lifesciences Limited is the fourth largest pharmaceutical company in India. Zydus Lifesciences was formerly known as Cadila Healthcare Limited.
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Apr-2022 | 376.60 | 337.70 | 359.37 |
| Mar-2022 | 379.00 | 331.00 | 359.62 |
| Feb-2022 | 420.50 | 343.00 | 385.95 |
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Apr-2022 | 376.70 | 337.55 | 359.43 |
| Mar-2022 | 378.60 | 331.55 | 359.63 |
| Feb-2022 | 420.55 | 342.85 | 385.99 |
The buyback is being undertaken for the following reason:
1. The Buyback will help the Company to distribute a part of the surplus cash to its shareholders holding Equity Shares thereby, optimizing returns to the shareholders and enhancing the overall shareholders' value in longer term and improving the return on equity.
Zydus Lifesciences Ltd.
Zydus Corporate Park, Scheme No. 63,
Khoraj (Gandhinagar), 536, Sarkhej-Gandhinagar Hwy
Near Vaishnodevi Circle, Ahmedabad, 382481
Ahmedabad, Gujarat, 382481
Lead Manager(s)
Registered Broker
The Zydus Lifesciences Buyback opens on June 23, 2022, and closes on July 6, 2022.
The Zydus Lifesciences Buyback last day to buy is not available as of now.
The Zydus Lifesciences Buyback is a Tender Offer.
Zydus Lifesciences Buyback Schedule
| Buyback Opening Date | June 23, 2022 |
| Buyback Closing Date | July 6, 2022 |
| Last Date for receipt of Tender Forms | July 6, 2022 |
| Finalisation of Buyback Acceptance | July 14, 2022 |
| Last Date for settlment of bids | July 15, 2022 |
| Last Date for Extinguishment of Shares | July 22, 2022 |
The Zydus Lifesciences Buyback is being offered at Rs ₹650 per share.
| Category | Entitlement Ratio of Buyback |
|---|---|
| Reserved Category for Small Shareholders | 26 Equity Share out of every 503 Fully paid-up Equity Shares held on the Record Date. |
| General Category for all other Eligible Shareholders | 1 Equity Shares out of every 101 Fully paid-up Equity Shares held on the Record Date. |
The issue size of Zydus Lifesciences Buyback is 1,15,38,461 equity shares at ₹650 per share aggregating up to ₹750.00 Crores.
The buyback is being undertaken for the following reason:
1. The Buyback will help the Company to distribute a part of the surplus cash to its shareholders holding Equity Shares thereby, optimizing returns to the shareholders and enhancing the overall shareholders' value in longer term and improving the return on equity.
All the eligible Shareholders of the Company holding either Physical Shares or Demat Shares as on the Record Date can participate in the buyback offer through their Stock Broker.
The eligible shareholder holding the shares in Demat form needs to inform their broker the details of the Equity shares they wish to tender in the Buyback Offer. The shareholder needs to transfer the tendered shares to a Special account of the clearing corporation. The broker, in turn, would place an order on the stock exchange for the buyback.
The eligible shareholder holding the shares in physical form needs to approach their broker with original share certificates and supporting documents. Upon completion of document verification, the broker places an order on the stock exchange and submits the original share certificate and TRS to the registrar.
The tender form and TRS are optional in the case of Demat shares but mandatory in the case of physical shares.
The Zydus Lifesciences Buyback offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.
